We studied 10 healthy subjects (controls) and 51 cirrhotic patients: 17 without HE, 14 with a minimal HE, 8 with overt HE, and 12 who had undergone a transjugular intrahepatic portosystemic shunt (TIPS) procedure. In the last group, blood was collected from the artery, and the portal and hepatic veins during TIPS construction and from the peripheral veins before, immediately after, and at weekly intervals during the fi rst month after TIPS.
INTRODUCTION
Hepatic encephalopathy (HE) is a complication of liver failure, characterized by a disturbance of mental state and neuromuscular function ( 1, 2 ) . Th e pathogenesis of HE is not completely clear. A series of observations, based on clinical and therapeutic features, suggest that for any substance to be involved in the pathogenesis of HE, it should originate in the gut, possibly by the action of bacteria, be found in the portal circulation, be increased in peripheral blood as the consequence of failing liver or portal systemic shunting, and fi nally should exert its eff ect on the brain. Unfortunately, any attempt to clarify the nature of the substance(s) involved has , until now, not been completely satisfactory. Ammonia meets all the above-mentioned criteria, but its correlation with HE is not always found. For example, ammonia can be increased to very high levels aft er a glutamine challenge without signifi cant changes in the patients ' mental state ( 3, 4 ) . Furthermore, concentrations of ammonia that are necessary to adversely aff ect the central nervous system of experimental animals are signifi cantly higher (in the m M range) than those commonly found in patients with overt HE. Among the other compounds proposed (such as mercaptans ( 5 ), short-chain fatty acids ( 6 ) , amines ( 7 ) , GABA ( γ -aminobutyric acid) ( 8 -10 ) Intestinal bacteria metabolize tryptophan into indole, which is then further metabolized into oxindole, a sedative compound putatively involved in the pathophysiology of hepatic encephalopathy (HE). The aim of this study was to measure indole and oxindole levels in patients with cirrhosis with or without HE and to establish whether an intestinal production and a hepatic metabolism of these substances exist.
LIVER endorphins ( 11 ) , glutamate ( 12, 13 ) , endogenous benzodiazepine agonists ( 14 -16 )), there is tryptophan and several of its metabolites ( 17, 18 ) , one of which is oxindole. Oxindole is a potent sedative agent that leads to coma when administered to rats ( 19 ) or humans ( 20 ) . Its actions have been ascribed to its ability of interacting with voltage-operated sodium channels ( 21 ) . Oxindole has been shown to be increased in the blood and brain of animal models of acute hepatic failure ( 22 ) . Th e direct precursor of oxindole is indole, which is in turn produced by tryptophan, by a process requiring the action of tryptophanase. Indole may thus be produced in the intestine by bacterial tryptophanase and may be metabolized into oxindole in several tissues, including the brain ( Figure 1 ). Indole, when administered to rats in rather high doses, has been shown to cross the blood -brain barrier and to increase oxindole brain levels ( 22 ) . Th us, it can be hypothesized that in patients with cirrhosis, indole produced in the intestine is no longer metabolized in the liver and is possibly eliminated by the intestine, but as such may reach the systemic circulation, thus contributing to the increase in brain oxindole levels. Peripheral plasma indole and oxindole concentrations were found to be elevated in the blood of cirrhotic patients, suggesting that the liver has a key role in the disposal of these neuroactive compounds ( 23, 24 ) . However, the intestinal production and the role of liver function in the synthesis and disposal of these tryptophan metabolites have not been previously investigated in humans. Th erefore, this study aimed to: (i) measure concentrations of indole and oxindole in cirrhotics with or without HE; (ii) measure the plasma concentration of these tryptophan metabolites before and aft er transjugular intrahepatic portosystemic shunt (TIPS) to study their modifi cations aft er the opening a large porto-systemic shunt; (iii) establish whether an intestinal production and hepatic metabolism of these substances exist by determining indole and oxindole concentration in the portal and hepatic veins and the artery; and (iv) evaluate possible relationships between indole and oxindole and post-TIPS HE.
METHODS

Patients
A total of 17 consecutive cirrhotic patients without HE (15 men; mean age 55 ± 8 years), 14 cases with a minimal HE (MHE) (12 men; mean age 67 ± 7 years), and 8 cases with overt HE (all men with a mean age of 62 ± 10 years), referred to our unit as outpatients or in-patients, were enrolled in this study 10 healthy subjects (blood donors) were used as controls. Th e demographic, clinical, and biochemical characteristics of these patients are reported in Table 1 . To estimate the severity of portal hypertension and the presence of spontaneous porta-caval shunts, all patients were subjected to abdominal ultrasound and upper gastrointestinal endoscopy close to inclusion in the study (during the same time of hospitalization). Th e presence and severity of esophageal varices ( Table 1 ) were similar among the three groups. Th e portal fl ow direction was normal in all patients, except in 1; the umbilical vein was patent in 4 patients and only 1 out of 39 patients showed the presence of a large spontaneous spleno-renal shunt. Th e distribution of these data among the three groups with or without HE was not statistically signifi cant 12 consecutive cirrhotic patients (11 men; mean age 54 ± 9 years) were also recruited into the study while waiting for a TIPS placement. Indications for TIPS were an acute or recurrent variceal bleeding refractory to the conventional therapy in fi ve patients and refractory ascites in seven. Anesthesiology ( 25 ) and TIPS technical details ( 26 ) were described previously . Th e demographic, clinical, and biochemical characteristics of TIPS patients are reported in Table 2 .
In all cases, the diagnosis of liver cirrhosis was based on clinical, biochemical, and / or histopathological data. At entry, the severity of liver disease was classifi ed according to the Child -Pugh ( 27 ) and the model for end-stage liver disease scores ( 28 ) .
Th e study was designed and conducted according to the principles of the Declaration of Helsinki, and a written informed consent was obtained by all the patients.
Evaluation of HE
In all cases, HE evaluation including examination and grading of their mental state, asterixis, and psychometric performance were obtained. Venous and arterial blood ammonia determinations were also assessed. Th e degree of HE was evaluated in the patient ' s mental state using modifi cations of the West Haven Criteria ( 29 ) . Th e mental state was assessed in each patient by the same investigator using standardized tests and questions, as described previously ( 30 ) . Th e trail-making test part-A (TMT-A), part-B (TMT-B), and the digit symbol (DS) were used to evaluate the patients ' psychometric performance. Results were expressed as Z -scores calculated as the diff erence between performance expected on the basis of predictive regression obtained from a healthy Italian population, adjusted for the main confounders Riggio et al.
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(such as age and education) according to the study by Amodio et al. ( 31 ) . Patients with at least one abnormal psychometric test ( Z -score > 2) were considered to have an MHE ( 30 ) . In the TIPS patient group, this workout (evaluation of mental status, psychometric performance, and ammonia determination) was repeated before and at weekly intervals during the fi rst month aft er the TIPS procedure (observation period). One of the four variations, of equal diffi culty, of the TMT-A and the TMT-B was used when the evaluation of the psychometric performance was repeated. None of the TIPS patients received any pharmacological treatment to prevent the occurrence of HE. Th e patients were then followed up as outpatients and seen at least every 3 months. All HE episodes that had occurred during follow-up were recorded.
Blood sampling
Blood samples for ammonia, indole, and oxindole determinations were collected immediately before either clinical or psychometric evaluation of HE. Aft er overnight fasting, venous blood samples were collected from all patients and control subjects to measure plasma concentrations of both indole and oxindole. Blood samples were collected in ice-chilled tubes and immediately centrifuged at 3,000 r.p.m. at 4 ° C for 15 min; plasma was then stored at − 80 ° C until the assay. Blood samples from a peripheral vein and the radial artery were collected in ice-chilled tubes for ammonia determination, which was carried out immediately aft er using the Ammonia Checker II (Menarini, Florence, Italy), as described previously ( 30 ) . Partial pressure of ammonia (pNH 3 ) was calcu- Evidence of P-C shunt was defi ned as the presence of hepatofugal portal fl ow or umbilical vein patency or spleno-renal shunt at abdominal US. lated from arterial ammonia and pH, according to Manning ' s nomogram ( 32 ) . In the TIPS patients, blood samples for the determination of ammonia, indole, and oxindole were collected from a peripheral vein and the radial artery before TIPS placement. A TIPS set (Angiodynamics, Queensbury, NY) was used to catheterize the hepatic vein and create the shunt. A blood sample from the hepatic vein was fi rst obtained. Once the portal vein was successfully punctured, a 5-F catheter was advanced into the portal vein distally to the confl uence between splenic and superior mesenteric veins and was used to collect further blood samples. All these samples were obtained before opening the shunt. Further blood samples were collected from a peripheral vein immediately aft er the shunt opening and at weekly intervals for the fi rst post-TIPS month or until death or liver transplantation.
Indole and oxindole determination
Indole plasma concentrations were measured using a procedure based on high-performance liquid chromatography separation and fl uorescence spectrophotometer detection ( 24 ) . Briefl y, 2 ml of pure methanol was added to 1 ml of plasma. Th e mixture was then centrifuged (18,000 g × 20 min), and an aliquot of the super natant was injected into the high-performance liquid chromatography apparatus. Th e column was an 18 SpheriSorb octadecyl silane (ODS) 10-μ m column (Alltech, Deerfi eld, IL) and the mobile phase was water / methanol (40 / 60 % ) at a fl ow rate of 1.2 ml / min. Detection was obtained at wavelengths of 285-nm excitation and 340-nm emission.
Oxindole plasma levels were evaluated as described previously ( 33 ): a volume of 2 ml HClO 4 0.4 N was added to 1 ml of plasma to precipitate proteins. Aft er centrifugation (18,000 g for 20 min), the supernatant was collected. Th e procedure was repeated to improve plasma extraction. Th e supernatants were then mixed with 8 ml of chloroform for at least 5 min. Th e organic layer was collected and evaporated under a stream of N 2 . Residues were dissolved in HClO 4 0.4 N (200 μ l), and a portion of it was injected into a highperformance liquid chromatography apparatus provided with an ultraviolet spectrophotometer detector. A 25-cm reverse-phase 18 SpheriSorb ODS 10-μ m column and a mobile phase of 0.5 M acetic acid / acetonitrile in a ratio of 90 / 10 % w.w. at a fl ow rate of 1.5 ml / min were used.
Calculations
Arterial (A), portal vein (PV), and hepatic vein (HV) concentrations were used to calculate the hepatic extraction ratio ((HV − PV concentration) / PV concentration × 100) and the intestinal production ratio ((PV − A concentration) / A concentration × 100).
Statistical analysis
Results were expressed as " mean ± s.d. " Comparisons among groups were performed for quantitative data by analysis of variance (ANOVA and Newman -Keuls test) or Student ' s t -test for unpaired or paired data when appropriate. Th e Wilcoxon signed rank test was used to test whether both the fractional hepatic extraction ratio and the fractional intestinal production ratio were diff erent from zero. Th e relationship between variables was analyzed by Pearson correlations. Th e Number Cruncher Statistical System soft ware (NCSS, Kaysville, UT) was used for computations.
RESULTS
Patient with or without HE
Mental state, psychometric performance (TMT-A, TMT-B, and DS), and ammonia levels, as well as data on the clinical characteristics obtained from the three groups of cirrhotic patients (without HE, with MHE, and with overt HE) are reported in Table 1 . Psychometric tests were not valuable in patients with overt HE and were altered in those with MHE. Th e severity of liver disease diff ered signifi cantly between the groups. Arterial, venous ammonia, and pNH 3 levels were signifi cantly higher in patients with overt HE than in cirrhotic patients with or without MHE.
Indole and oxindole plasma levels in the three groups of cirrhotic patients and in healthy controls are shown in Figure 2 . Both indole (0.407 ± 0.347 vs. 0.017 ± 0.01; P = 0.002) and oxindole (0.162 ± 0.168 vs. 0.03 ± 0.002; P = 0.019) plasma levels were signi-Riggio et al.
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complete the 28-day observation period, the last available sample was considered. Compared with basal values, plasma indole levels (similar to plasma ammonia levels) signifi cantly increased aft er TIPS. However, plasma oxindole levels did not signifi cantly change aft er the procedure.
No patient developed overt episodes of HE during the 1-month observation period. The patients ' psychometric performance was evaluated weekly until death, liver transplantation, or the end of the observation period. No incidental MHE occurred. In fact, all five patients with MHE before TIPS continued to have MHE even after the procedure. However, we observed that the TIPS induced variations in indole and TMT-B were significantly correlated ( r = 0.69; P < 0.05). Moreover, after TIPS, the time required to complete TMT-B increased particularly in four patients (all with MHE before TIPS). In these four patients, the increment in indole concentration was higher than in those in whom TMT-B was unmodified after the TIPS ( Table 3 ). Finally, after discharge, we recorded an overt fi cantly higher in cirrhotic patients, compared with healthy subjects. Indole concentrations were signifi cantly higher in patients with overt HE than in cirrhotic patients with or without MHE. Th is diff erence was not recorded for oxindole plasma levels. A signifi cant correlation between indole and venous ammonia levels was observed ( Figure 3 ). Venous oxindole was inversely correlated with model for end-stage liver disease score ( r = − 0.32; P = 0.02). Venous ammonia (34 ± 21 vs. 41 ± 34 nmol / ml; P = 0.45) and indole (0.338 ± 0.29 vs. 0.339 ± 0.4 nmol / ml; P = 0.98) concentrations were similar in patients with both small and large varices. Ammonia (33 ± 25 vs. 37 ± 27 nmol / ml; P = 0.70) and indole (0.13 ± 0.07 vs. 0.37 ± 0.34 nmol / ml; P = 0.09) concentrations were also similar in patients with or without evidence of hepatofugal portal fl ow or umbilical vein patency or spleno-renal shunt, suggesting that the increment in both ammonia and indole observed in patients with HE are not merely attributable to a higher degree of shunting of the portal blood.
TIPS patients
Individual values of arterial, portal, and hepatic vein indole and ammonia plasma levels, as well as hepatic extraction and intestinal production fractions of plasma indole and venous ammonia are shown in Figure 4 . Both indole and ammonia were produced in the intestine (indole production = + 196 ± 204 % , P = 0.011; ammonia production fraction = + 160 ± 133 % , P = 0.0025) and cleared by the liver (indole hepatic extraction ratio = − 54 ± 19 % , P = 0.003; ammonia hepatic extraction ratio = − 46 ± 25 % , P = 0.005). Oxindole plasma concentrations were below detection levels in several portal samples; therefore, no calculations on intestinal or hepatic production and removal were performed.
Five patients died; two during the 1-month observation period (23 and 27 days aft er TIPS, respectively) and three during the subsequent follow-up. One patient underwent liver transplantation during the observation period (2 weeks aft er TIPS). Figure 5 shows data on indole, oxindole, and ammonia determination in the 12 TIPS patients before and immediately aft er the procedure, aft er 7 days, and at the end of the observation period. In patients who did not 
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LIVER episode of HE in four patients (three of whom had MHE before and after TIPS). The TIPS-induced increment in indole concentration observed in these four patients tended to be higher than that observed in those who did not develop any episode of HE during follow-up ( + 0.96 ± 0.6 vs. + 0.34 ± 0.25 nmol / ml; P = 0.057).
DISCUSSION
In this paper, we showed that indole signifi cantly increases (at least 20-fold) in the plasma of cirrhotic patients and is particularly elevated in patients with overt HE ( ~ 50-fold; see Figure 2 ). Moreover, we found a signifi cant correlation between plasma ammonia and indole concentrations. By determining the indole concentration in the artery, and splanchnic and peripheral veins during TIPS construction, we showed that in cirrhotic patients, indole can be generated in the intestine and removed by the liver. Th e pattern of indole concentration in the portal and hepatic veins and systemic circulations does not diff er from that of ammonia, a compound known to originate from the intestine and to be removed by the liver. Similar to ammonia, indole was in fact produced by the intestine as shown by the observation that indole plasma levels in the portal circulation was higher than in peripheral arteries and at least partially removed from the portal blood by the liver, as shown by the lower levels seen in the hepatic vein compared with those observed in the portal vein (see Figure 4 ). Plasma indole concentrations, similar to plasma ammonia levels, increased aft er TIPS opening and remained high during the whole observation period ( Figure 5 ), further confi rming that at least part of the circulating indole levels are produced in the intestine and reach the peripheral blood when a large portal-systemic shunt is present. Interestingly, we found a correlation between the changes of psychometric tests and indole plasma levels aft er TIPS. As mentioned previously, it is reasonable to assume that indole is metabolized into oxindole, the neuroactive metabolite. Oxindole formation (see Figure 1 ) requires the action of oxidative enzymes 
Study Highlights
WHAT IS CURRENT KNOWLEDGE
3 Oxindole is a potent sedative agent that can lead to coma.
It has been shown to be increased in the blood and brain of animal models of acute hepatic failure and in the blood of cirrhotic patients.
3 Oxindole can be produced in several tissues, including the brain, by its precursor indole, which is in turn produced by tryptophan, by a process requiring the action of tryptophanase.
3 Indole, when administered to rats in rather high doses, has been shown to cross the blood -brain barrier and to increase oxindole brain levels.
WHAT IS NEW HERE
3 Indole signifi cantly increased in the plasma of cirrhotic patients and was particularly elevated in patients with overt hepatic encephalopathy (HE).
that are expressed in most mammalian cells and are present in the gut mucosa, the liver, the kidneys, the leukocytes, and even in the brain tissue ( 22 ) . Th is may explain the rather high variability of plasma oxindole levels in cirrhotic patients in whom the liver (and kidney) function is signifi cantly impaired. In a different series of patients who were studied 10 years ago, we found that peripheral plasma oxindole levels were extremely high in cirrhosis and somewhat correlated with signs of HE ( 23 ) . In this series, we could not show that peripheral oxindole correlated with HE severity as those patients with MHE had plasma oxindole levels not diff erent from those with overt HE (see Figure 2 ) . Possibly, when the liver function is particularly damaged or the number of circulating leukocytes is reduced (as in patients with hepatitis C virus), peripheral oxindole synthesis becomes rather slow and its plasma accumulation is no longer proportional to plasma indole levels. Th is interpretation is supported by the inverse correlation found between venous oxindole and model for end-stage liver disease score. We do not have information on brain oxindole synthesis and levels in humans, but it is known that in rats and other mammals, brain oxindole levels significantly increase, in a dose-dependent manner, aft er peripheral indole administration ( 19, 22, 34 ) . Blood levels of indole may be a better index of brain oxindole formation rather than blood levels of oxindole itself. On the basis of the above fi ndings, we hypothesize that indole produced in the intestine reaches the systemic circulation when the liver fails and / or large shunts are present and may be transformed into oxindole in the brain, thereby fi tting all the features in order to be considered a substance with potential involvement in the pathogenesis of HE. In fact, oxindole, the main indole metabolite, interacts with neuronal voltage-operated sodium channels, thus reducing cell excitability ( 21 ) and contributing to the changes in brain function found in HE. As ammonia has been shown to interact with diff erent neuronal and glial targets (for instance, with molecular mechanisms controlling glutamate synthesis and release ( 12 )), it is possible that the basic actions of oxindole and ammonia additively contribute to the development of the signs and symptoms found in HE.
Considering the gut origin of indole, it is possible that, similar to what occurs in the case of ammonia, plasma indole levels would also be reduced by most of the treatments traditionally used in patients with overt HE, such as gut cleansing ( 34 ), non-absorbable disaccharides, or low-absorbable antibiotics ( 29 ) . Moreover, as tryptophan is an indole precursor, a vegetable diet low in tryptophan content should decrease indole formation. Finally, an attempt should be carried out to modify the gut fl ora by administering probiotics without tryptophanases (unable to metabolize tryptophan into indole, see Figure 1 ).
In conclusion, similar to ammonia, indole correlates with the presence of overt HE in patients with liver cirrhosis; it has an intestinal production and is metabolized by the liver; moreover, its plasmatic levels increase aft er TIPS, particularly in those patients with a modifi cation of their psychometric performances aft er the procedure. On the basis of these data, we therefore suggest that indole may be a new putative toxin involved in the pathogenesis of HE.
